Physician profile
John N Olsofka
NPI 1013919273
$42,181.95
in general payments reported to CMS, 2019-2025
35 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,165 · 2020: $293 · 2021: $35K · 2022: $1,081 · 2023: $1,464 · 2024: $986 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reshape Lifesciences INC. | $35,110.38 | 2019-2023 | |
| Davol INC. | $3,861.63 | 2019-2025 | Phasix Mesh, Ventralight St |
| Enterra Medical, INC. | $850.54 | 2022-2025 | |
| Intuitive Surgical, INC. | $315.71 | 2019-2023 | |
| Pacira Pharmaceuticals Incorporated | $239.93 | 2020-2021 | |
| Ethicon US, LLC | $210.36 | 2019-2025 | Echelon Flex, Ethicon, Stratafix |
| Vertex Pharmaceuticals Incorporated | $163.75 | 2025 | |
| Phathom Pharmaceuticals, INC. | $158.26 | 2024 | Voquezna |
| Stryker Corporation | $150.00 | 2022 | |
| Medtronic, INC. | $149.54 | 2024-2025 | Tacker, Maxtack |
| Acacia Pharma INC | $133.98 | 2021 | |
| Tela Bio, INC. | $122.10 | 2020-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Novo Nordisk INC | $95.50 | 2022-2023 | Wegovy |
| Kerecis Limited | $81.24 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Endogastric Solutions, INC | $75.04 | 2023 | Esophyx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $66.34 | 2021 | |
| Integra Lifesciences Corporation | $48.40 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Sanara Medtech INC. | $38.64 | 2021 | |
| Aroa Biosurgery Incorporated | $27.12 | 2019 | |
| Avita Medical Americas, LLC | $26.40 | 2024 | |
| Hologic Sales and Service, LLC | $24.41 | 2025 | Coolseal Generator |
| Ambu INC. | $23.48 | 2022 | |
| Daiichi Sankyo INC. | $22.59 | 2022 | |
| Innocoll Pharmaceuticals Limited | $21.58 | 2021 | |
| Baxter Healthcare | $21.29 | 2024 | Perclot |
| Polynovo North America LLC | $21.27 | 2025 | Novosorb Btm |
| Braintree Laboratories, INC. | $19.29 | 2025 | Suflave |
| W. L. Gore & Associates, INC. | $18.34 | 2023 | Seamguard |
| Organogenesis INC. | $17.96 | 2024 | |
| Avanos Medical | $13.94 | 2022 | |
| Bioventus LLC | $13.61 | 2023 | Sonicone Clinic |
| Tetraphase Pharmaceuticals, INC. | $13.61 | 2019 | |
| Smith+Nephew, INC. | $13.40 | 2024 | Renasys Touch |
| Baudax Bio INC. | $12.32 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Olsofka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.